- Home
- FNA vs PHVS Comparison
FNA vs PHVS Comparison
Compare FNA & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FNA
- PHVS
- Stock Information
- Founded
- FNA 2010
- PHVS 2015
- Country
- FNA United States
- PHVS Netherlands
- Employees
- FNA N/A
- PHVS N/A
- Industry
- FNA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- FNA Health Care
- PHVS Health Care
- Exchange
- FNA Nasdaq
- PHVS Nasdaq
- Market Cap
- FNA 910.9M
- PHVS 1.0B
- IPO Year
- FNA 2021
- PHVS 2021
- Fundamental
- Price
- FNA $10.89
- PHVS $18.36
- Analyst Decision
- FNA Strong Buy
- PHVS Strong Buy
- Analyst Count
- FNA 5
- PHVS 5
- Target Price
- FNA $15.60
- PHVS $40.60
- AVG Volume (30 Days)
- FNA 533.4K
- PHVS 47.5K
- Earning Date
- FNA 02-27-2025
- PHVS 11-13-2024
- Dividend Yield
- FNA N/A
- PHVS N/A
- EPS Growth
- FNA N/A
- PHVS N/A
- EPS
- FNA N/A
- PHVS N/A
- Revenue
- FNA $244,995,000.00
- PHVS N/A
- Revenue This Year
- FNA $18.58
- PHVS N/A
- Revenue Next Year
- FNA $14.85
- PHVS N/A
- P/E Ratio
- FNA N/A
- PHVS N/A
- Revenue Growth
- FNA 18.16
- PHVS N/A
- 52 Week Low
- FNA $4.65
- PHVS $15.21
- 52 Week High
- FNA $14.79
- PHVS $33.00
- Technical
- Relative Strength Index (RSI)
- FNA 60.29
- PHVS 48.93
- Support Level
- FNA $10.11
- PHVS $15.21
- Resistance Level
- FNA $11.10
- PHVS $19.59
- Average True Range (ATR)
- FNA 0.61
- PHVS 1.39
- MACD
- FNA -0.04
- PHVS -0.02
- Stochastic Oscillator
- FNA 84.80
- PHVS 67.31
About FNA Paragon 28 Inc.
Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including ankle, Charcot, fracture fixation, hallux valgus, hammertoe, and flat foot. The company's suite of surgical solutions comprises nearly 80 product systems to help fit the specific needs of each patient and procedure. Geographically the company generates the majority of its revenue from the United States.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.